Hyperhomocysteinemia also reduces the efficacy of antithrombin III by inhibiting its binding capabilities to the vessel wall endothelium [12]. Hyperhomocysteinemia leads to numerous downstream effects, which result in a prothrombotic state, such as platelet aggregation and the inactivation of protein C [12]. This evidence concerns the gene SERPINC1 and hyperhomocysteinemia.